A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~41 mi. (Córdoba, Spain, +89 more cities)
facility
Hospital Universitario Reina Sofia; Servicio de Farmacia
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +1 more drug
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
city
~41 mi. (Córdoba, Spain, +39 more cities)
facility
Novartis Investigative Site
condition
Fallopian Tube Carcinoma, +3 more conditions
drug
alpelisib, +1 more drug